Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
Medtronic
Fuji
Argus Health
Deloitte
UBS
Mallinckrodt
US Army
Moodys

Generated: January 18, 2018

DrugPatentWatch Database Preview

ORAVERSE Drug Profile

« Back to Dashboard

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-three patent family members in twenty countries.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
Summary for ORAVERSE
Drug patent expirations by year for ORAVERSE
Pharmacology for ORAVERSE
Medical Subject Heading (MeSH) Categories for ORAVERSE

US Patents and Regulatory Information for ORAVERSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ORAVERSE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,401 Local anesthetic methods and kits ➤ Subscribe
7,261,889 Local anesthetic methods and kits ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ORAVERSE

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Citi
Colorcon
Harvard Business School
Chinese Patent Office
Accenture
Fish and Richardson
Cerilliant
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot